Table I.

Therapeutic treatment with Salmonella vaccines after PLP_139–151 challenge protects SJL/J mice from EAEa

Treatmentb	EAE/Totalc	Onsetd	Max. Scoree	CSf	Inflammationg	Demyelinationh
PBS	15/15	9.2 ± 0.4	5	54.0 ± 2.8	2.0 ± 0.9	2.9 ± 0.31
AP331	15/15	11.2 ± 1.3	2	11.6 ± 0.4*,*	0.8 ± 0.3*,*	1.1 ± 0.2*,*
H647	15/15	10.8 ± 0.4	5	25.0 ± 1.5*	2.1 ± 0.1	2.4 ± 0.1
H696	15/15	10.9 ± 0.4	2	13.2± 0.4 *,*	0.7 ± 0.3*,*	1.0 ± 0.1*,*

^aSJL/J mice were challenged s.c. with 200 μg PLP_139–151 in complete Freund’s adjuvant plus 200 ng PT i.p. on days 0 and 2.

^bMice were immunized 6 days post-challenge with PBS or 5 × 10⁹ CFU of S. enterica Typhimurium H647 (vector), H696 (CFA/I fimbriae),

or AP331 (CFA/I_IC fimbriae).

^cNumber of mice with EAE/total in group.

^dMean day ± SD of clinical disease onset.

^eMaximum (Max.) daily clinical score.

^fCumulative scores (CS) were calculated as the sum ± SEM of all scores from disease onset to day 26 post-challenge, divided by the number of mice in each group. * P < 0.001 for PBS vs. treated groups; H647- vs. H696-treated groups; and H647- vs. AP331-treated groups.

^gMean score ± SEM of inflammation: the infiltration of nucleated cells into spinal cords was scored from 0 to 4 in each mouse separately, and the mean score ± SEM was calculated. *, P < 0.001 for PBS vs. AP331- or H696-treated groups; H647- vs. H696-treated groups; and H647- vs. AP331-treated groups.

^hMean score ± SEM of demyelination: of spinal cords was scored from 0 to 4 in each mouse separately, and the mean score ± SEM was calculated. *, P < 0.001 for PBS vs. H696- or AP331-treated groups; H647- vs. H696-treated groups; and H647- vs. AP331-treated groups.

ⁱ% CD4⁺ TCRβ⁺ T cells from the total cells in spinal cords, analyzed by FACS (Fig. 1C).*, P < 0.001 for PBS vs. treated groups; H647- vs. H696-treated groups; and H647- vs. AP331-treated groups.